References
- Lo YMD, Lo ES, Watson N, et al. Two-way cell traffic between mother and fetus: biologic and clinical implications. Blood 1996;88:4390–5
- Bischoff FZ, Lewis DE, Simpson JL. Cell-free fetal DNA in maternal blood: kinetics, source and structure. Human Reproduction Update. 2004 November;11:59–67
- Lo YMD, Zhang J, Leung TN, et al. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Gen 1999;64:218–24
- Wright CF, Burton H. The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis. Human Reproduction Update. 2009 October;15:139–51
- Rijnders RJ, Christiaens GC, Bossers B, et al. Clinical applications of cell-free fetal DNA from maternal plasma. Obstet Gynecol 2004;103:157–64
- Chetty S, Garabedian MJ, Norton ME. Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening. Prenat Diagn 2013. [Epub ahead of print]. doi:10.1002/pd.4125
- Fairbrother G, Johnson S, Musci TJ, et al. Clinical experience of noninvasive prenatal testing with cell-free DNA for fetal trisomies 21, 18, and 13, in a general screening population. Prenat Diagn 2013;15:1–5
- Allyse MA, Sayres LC, Havard M, et al. Best ethical practices for clinicians and laboratories in the provision of non-invasive prenatal testing. Prenat Diagn 2013. [Epub ahead of print]. doi:10. 1002/pd. 4144
- Vergani P, Locatelli A, Biffi A, et al. Factors affecting the decision regarding amniocentesis in women at genetic risk because of age 35 years or older. Prenatal Diagn 2002;22:769–74
- Vintzileos AM, Guzman ER, Smulian JC, et al. Choice of second-trimester genetic sonogram for detection of trisomy 21. Obstet Gynecol 1997;90:187–90
- ACOG Committee Opinion Number 545: Noninvasive Prenatal Testing for Fetal Aneuploidy. Obstet Gynecol. 2012;120:1532–4